Ceylad kicks off SHRINK trial targeting metastatic colorectal patients
July 20, 2017Celyad has kicked off the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients, the company said Thursday.
SHRINK ( S tandard C H emotherapy R egimen and I mmunotherapy with NK R-2) is an open-label Phase I study evaluating the safety and clinical activity of multiple doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.
Dr. Christian Homsy, CEO of Celyad said that the trial will allow the company to evaluate the efficiency of its CYAD-01 therapy in combination with chemotherapy. Homsey is confident that the partnership with major Belgian cancer institutions will provide new insights in the treatment of metastatic colorectal cancer. “Today’s announcement, in conjunction with our ongoing THINK trial and the upcoming LINK study, reaffirms our commitment and dedication to beat cancer with a strong focus on solid tumors.”
Dr. Frédéric Lehmann, VP Clinical Development and Medical Affairs at Celyad said: “As leaders in our field, it is our task to further develop the potential of our CAR-T treatments. Starting SHRINK is another important milestone for us and for patients worldwide, evaluating the synergetic effect of the concurrent administration of our lead candidate CYAD-01 with standard chemotherapy as first-line treatment for metastatic colorectal cancers.”
He added that the SHRINK study is one of the new Celyad studies to be initiated in 2017 as part of a global comprehensive clinical program supporting the development of our CYAD-01 candidate.
